Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lowered by equities researchers at Bernstein Bank from $1,070.00 to $1,000.00 in a research note issued to investors on ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on Tuesday said its board ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

To gain a panoramic view of Regeneron Pharmaceuticals's market performance ... downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.